How much does a course of treatment with Telisotuzumab cost?

Telisotuzumab vedotin (Telisotuzumab vedotin, trade name Teliso-V) has not yet been approved for marketing by the National Food and Drug Administration (NMPA) in China, so it cannot be purchased through formal domestic channels. The drug is primarily used to treat patients with c-Met-positive non-small cell lung cancer (NSCLC), especially those who have not responded to previous treatment. In the United States, the recommended dose of Telisotuzumab vedotin is 1.9 mg/kg body weight every two weeks, or 2.7 mg/kg body weight every three weeks.

According to U.S. drug price information, Telisotuzumab vedotin’s treatment cost per cycle is approximately **$31,500**, which is approximately RMB22 yuan. The annual treatment cost is estimated to be **$781,500**, which is approximately RMB 550 yuan. It’s important to note that these costs may vary based on patient weight, treatment duration, and healthcare provider.

Currently, Telisotuzumab vedotin is not yet available in China and therefore cannot be reimbursed through medical insurance. If patients wish to use the drug, they may need to participate in international clinical trials or purchase it through formal overseas channels, but this usually involves complex import procedures and higher costs. When choosing these avenues, patients should ensure that the source of drugs is legitimate and avoid purchasing fake and shoddy products.

In summary,Telisotuzumab vedotinIt is not currently on the market in China, and patients cannot purchase the drug through formal domestic channels. Before considering using this drug, patients should seek professional medical advice and pay attention to the latest announcements from relevant departments. With global medical progress and the improvement of China's drug approval system, the drug is expected to enter the Chinese market through approval in the future and may be included in the medical insurance system to reduce the financial burden on patients.

Reference materials:https://www.drugs.com/